Barbara J Gitlitz - JoVE Visualize

Showing results (31-40 of 41) with videos related to

Pageof 5

Sort By:

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2011

Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumorsAdil I Daud, Smitha S Krishnamurthi, Mansoor N Saleh, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2016

HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to AfatinibSai-Hong Ignatius Ou, Alexa B Schrock, Eduard V Bocharov, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2025

Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III TrialEnriqueta Felip, Nasser Altorki, Caicun Zhou, et al.

Cancer Chemotherapy and Pharmacology|November 23, 2011

A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium StudyJoseph Chao, Timothy W Synold, Robert J Morgan, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2018

Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter StudyLeora Horn, Jeffrey R Infante, Karen L Reckamp, et al.

JAMA Oncology|June 23, 2018

Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical TrialRobert L Ferris, Nabil F Saba, Barbara J Gitlitz, et al.

Cancer Discovery|April 23, 2016

EGFR Fusions as Novel Therapeutic Targets in Lung CancerKartik Konduri, Jean-Nicolas Gallant, Young Kwang Chae, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2018

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)Brigette B Y Ma, Wan-Teck Lim, Boon-Cher Goh, et al.

Nature Communications|November 29, 2017

Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAsIvan Vannini, Petra M Wise, Kishore B Challagundla, et al.

Nature Communications|January 10, 2018

Publisher Correction: Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAsIvan Vannini, Petra M Wise, Kishore B Challagundla, et al.

Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:

Pageof 5

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2011

Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumorsAdil I Daud, Smitha S Krishnamurthi, Mansoor N Saleh, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2016

HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to AfatinibSai-Hong Ignatius Ou, Alexa B Schrock, Eduard V Bocharov, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2025

Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III TrialEnriqueta Felip, Nasser Altorki, Caicun Zhou, et al.

Cancer Chemotherapy and Pharmacology|November 23, 2011

A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium StudyJoseph Chao, Timothy W Synold, Robert J Morgan, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2018

Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter StudyLeora Horn, Jeffrey R Infante, Karen L Reckamp, et al.

JAMA Oncology|June 23, 2018

Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical TrialRobert L Ferris, Nabil F Saba, Barbara J Gitlitz, et al.

Cancer Discovery|April 23, 2016

EGFR Fusions as Novel Therapeutic Targets in Lung CancerKartik Konduri, Jean-Nicolas Gallant, Young Kwang Chae, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2018

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)Brigette B Y Ma, Wan-Teck Lim, Boon-Cher Goh, et al.

Nature Communications|November 29, 2017

Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAsIvan Vannini, Petra M Wise, Kishore B Challagundla, et al.

Nature Communications|January 10, 2018

Publisher Correction: Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAsIvan Vannini, Petra M Wise, Kishore B Challagundla, et al.

Pageof 5